HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

fotagliptin

a dipeptidyl peptidase IV inhibitor; structure in first source

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Triazines: 306
    - fotagliptin: 3
  - Piperidines: 17
    - fotagliptin: 3

Experts

1.	Ding, Yan-Hua: 1 article (01/2021)
2.	Li, Qian-Qian: 1 article (01/2021)
3.	Li, Xiao-Jiao: 1 article (01/2021)
4.	Li, Ying: 1 article (01/2021)
5.	Sun, Hai-Gang: 1 article (01/2021)
6.	Wu, Min: 1 article (01/2021)
7.	Zhang, Hong: 1 article (01/2021)
8.	Zhu, Xiao-Xue: 1 article (01/2021)
9.	Hu, Pei: 1 article (02/2017)
10.	Jiang, Ji: 1 article (02/2017)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 10/09/2023 - "Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial." 01/01/2021 - "This study investigated the pharmacokinetics, pharmacodynamics, and safety of fotagliptin benzoate (fotagliptin), a dipeptidyl peptidase-4 (DPP-4) inhibitor, in Chinese patients with type 2 diabetes mellitus (T2DM). " 01/01/2021 - "Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus." 10/09/2023 - "Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control in type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, which was designed to assess the efficacy and safety of a novel DPP-4 inhibitor fotagliptin in treatment-naive patients with T2DM. "
2.	Hypoglycemia (Reactive Hypoglycemia) 10/09/2023 - "During the whole 52 weeks of treatment, the overall incidence of hypoglycemia was low for both of the fotagliptin and alogliptin groups (1.0% each). "
3.	Diabetes Mellitus 02/01/2017 - "Fotagliptin is a novel dipeptidyl peptidase IV inhibitor under clinical development for the treatment of Type II diabetes mellitus. "

Related Drugs and Biologics

1.	Benzoates (Benzoate)
2.	alogliptin
3.	Dipeptidyl-Peptidase IV Inhibitors

Related Therapies and Procedures

1.	Glycemic Control